Vincerx Pharma Inc (VINC)
$0.7
Insights on Vincerx Pharma Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 113.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 327.7%
Performance
- $0.68$0.73$0.70
2.57%
Downside
Day's Volatility :6.84%
Upside
4.38%
- $0.61$9.37$0.70
12.86%
Downside
52 Weeks Volatility :93.49%
Upside
92.53%
Returns
| Period | Vincerx Pharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -81.21% | 0.0% |
6 Months | 3.53% | 0.0% |
1 Year | -55.17% | 0.0% |
3 Years | -94.92% | -20.1% |
Highlights
Market Capitalization | 20.2M |
Book Value | $0.52 |
Earnings Per Share (EPS) | -1.89 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -68.72% |
Return On Equity TTM | -136.38% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -42.6M |
Diluted Eps TTM | -1.89 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.05 |
EPS Estimate Next Year | -0.76 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.22 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 900.0%
Technicals Summary
Sell
Neutral
Buy
Vincerx Pharma Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Vincerx Pharma Inc | -17.19% | 3.53% | -55.17% | -94.92% | -96.32% |
 Moderna, Inc. | 37.56% | 83.82% | 13.37% | -12.47% | 553.14% |
 Regeneron Pharmaceuticals, Inc. | 10.42% | 24.29% | 32.26% | 98.6% | 210.52% |
 Novo Nordisk A/s | 7.9% | 30.89% | 58.53% | 230.87% | 458.51% |
 Vertex Pharmaceuticals Incorporated | 10.52% | 25.13% | 30.01% | 109.26% | 156.43% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Vincerx Pharma Inc | NA | NA | NA | -1.05 | -1.36 | -0.69 | NA | 0.52 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.46 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.16 | 29.16 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 45.83 | 45.83 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.9 | 28.9 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Vincerx Pharma Inc | Buy | $20.2M | -96.32% | NA | 0.0% |
Moderna, Inc. | Buy | $54.0B | 553.14% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.8B | 210.52% | 29.16 | 29.45% |
Novo Nordisk A/s | Buy | $592.1B | 458.51% | 45.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $115.1B | 156.43% | 28.9 | 39.46% |
Institutional Holdings
Goldman Sachs Group Inc
14.53%SAGE RHINO CAPITAL LLC
7.24%Long Focus Capital Management, LLC
4.67%Bank of America Corp
4.60%Octagon Capital Advisors LP
4.25%Rock Springs Capital Management LP
3.79%
Company Information
vincerx is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.
Organization | Vincerx Pharma Inc |
Employees | 42 |
CEO | Dr. Ahmed M. Hamdy M.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$0.70
-2.72%
Keyarch Acquisition Corp
$0.70
-2.72%
Connexa Sports Technologies Inc
$0.70
-2.72%
Us Value Etf
$0.70
-2.72%
First Wave Biopharma Inc
$0.70
-2.72%
Global X Msci Next Emerging
$0.70
-2.72%
Fat Projects Acquisition Corp
$0.70
-2.72%
Ishares Intl Div Growth Etf
$0.70
-2.72%
Corsair Gaming, Inc.
$0.70
-2.72%